{"filing":{"accession_number":"0001193125-26-285425","cik":"0001810182","ticker":"ALXO","company_name":"ALX ONCOLOGY HOLDINGS INC","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"alxo-20260625.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526285425/alxo-20260625.htm"},"events":[{"id":14201,"run_id":12632,"accession_number":"0001193125-26-285425","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"ALX Oncology entered into a loan and security agreement with HSBC Ventures USA Inc. on June 25, 2026, establishing a secured multi-tranche term loan facility of up to $50 million with $10 million borrowed at closing, maturing June 1, 2030. The company simultaneously terminated its prior loan agreement dated October 27, 2022, by using proceeds from the new facility to pay off all outstanding amounts, constituting a material debt refinancing transaction.","company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11562,"accession_number":"0001193125-26-285425","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ALX Oncology entered into a loan and security agreement with HSBC Ventures USA Inc. on June 25, 2026, creating a secured multi-tranche term loan facility of up to $50 million, with $10 million borrowed at closing. This is a material creation of a new direct financial obligation, distinct from a covenant breach or refinancing of existing debt. The disclosure details the facility structure, interest rates, maturity date (June 1, 2030), amortization schedule, and customary covenants typical of a debt issuance under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:04:47.407451+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11563,"accession_number":"0001193125-26-285425","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses termination of an existing loan agreement dated October 27, 2022, by paying off all outstanding amounts using proceeds from a new \"Loan Agreement\" (Term Loans). While Item 1.02 addresses termination, the material event is the refinancing transaction itself—entry into new debt obligations to retire existing debt. This is a debt refinancing, which is a material capital event affecting the registrant's financial obligations and structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:04:47.407451+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11564,"accession_number":"0001193125-26-285425","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.03 explicitly addresses creation of a direct financial obligation through a Loan Agreement, which is incorporated by reference from Item 1.01. This is a debt issuance event — the creation of a new direct financial obligation through a loan facility. Such obligations are material to investors assessing the registrant's capital structure and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:04:47.407451+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11562,"accession_number":"0001193125-26-285425","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ALX Oncology entered into a loan and security agreement with HSBC Ventures USA Inc. on June 25, 2026, creating a secured multi-tranche term loan facility of up to $50 million, with $10 million borrowed at closing. This is a material creation of a new direct financial obligation, distinct from a covenant breach or refinancing of existing debt. The disclosure details the facility structure, interest rates, maturity date (June 1, 2030), amortization schedule, and customary covenants typical of a debt issuance under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:04:47.407451+00:00","company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","filing_date":"2026-06-26"},{"id":11563,"accession_number":"0001193125-26-285425","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses termination of an existing loan agreement dated October 27, 2022, by paying off all outstanding amounts using proceeds from a new \"Loan Agreement\" (Term Loans). While Item 1.02 addresses termination, the material event is the refinancing transaction itself—entry into new debt obligations to retire existing debt. This is a debt refinancing, which is a material capital event affecting the registrant's financial obligations and structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:04:47.407451+00:00","company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","filing_date":"2026-06-26"},{"id":11564,"accession_number":"0001193125-26-285425","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.03 explicitly addresses creation of a direct financial obligation through a Loan Agreement, which is incorporated by reference from Item 1.01. This is a debt issuance event — the creation of a new direct financial obligation through a loan facility. Such obligations are material to investors assessing the registrant's capital structure and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:04:47.407451+00:00","company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","filing_date":"2026-06-26"}]}